RCKT ROCKET PHARMACEUTICALS, INC.

Nasdaq rocketpharma.com


$ 3.71 $ -0.29 (-7.25 %)    

Friday, 17-Oct-2025 19:39:56 EDT
QQQ $ 604.92 $ 3.94 (0.66 %)
DIA $ 461.73 $ 2.22 (0.48 %)
SPY $ 665.28 $ 3.75 (0.57 %)
TLT $ 91.09 $ -0.14 (-0.15 %)
GLD $ 391.28 $ -7.46 (-1.88 %)
$ 3.71
$ 3.92
$ 3.71 x 87
$ 3.81 x 2
$ 3.63 - $ 3.94
$ 2.19 - $ 18.89
2,890,314
na
400.32M
$ 1.33
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-07-2025 06-30-2025 10-Q
2 05-08-2025 03-31-2025 10-Q
3 02-27-2025 01-01-1970 10-K
4 02-27-2025 12-31-2024 10-K
5 11-07-2024 09-30-2024 10-Q
6 08-06-2024 06-30-2024 10-Q
7 05-07-2024 03-31-2024 10-Q
8 02-27-2024 12-31-2023 10-K
9 11-07-2023 09-30-2023 10-Q
10 08-09-2023 06-30-2023 10-Q
11 05-05-2023 03-31-2023 10-Q
12 02-28-2023 12-31-2022 10-K
13 11-04-2022 09-30-2022 10-Q
14 08-09-2022 06-30-2022 10-Q
15 05-06-2022 03-31-2022 10-Q
16 02-28-2022 12-31-2021 10-K
17 11-05-2021 09-30-2021 10-Q
18 08-09-2021 06-30-2021 10-Q
19 05-10-2021 03-31-2021 10-Q
20 03-01-2021 12-31-2020 10-K
21 11-06-2020 09-30-2020 10-Q
22 08-05-2020 06-30-2020 10-Q
23 05-08-2020 03-31-2020 10-Q
24 03-06-2020 12-31-2019 10-K
25 11-08-2019 09-30-2019 10-Q
26 08-08-2019 06-30-2019 10-Q
27 05-09-2019 03-31-2019 10-Q
28 03-08-2019 12-31-2018 10-K
29 11-09-2018 09-30-2018 10-Q
30 08-14-2018 06-30-2018 10-Q
31 05-11-2018 03-31-2018 10-Q
32 03-07-2018 12-31-2017 10-K
33 11-08-2017 09-30-2017 10-Q
34 08-03-2017 06-30-2017 10-Q
35 05-10-2017 03-31-2017 10-Q
36 03-16-2017 12-31-2016 10-K
37 11-09-2016 09-30-2016 10-Q
38 08-10-2016 06-30-2016 10-Q
39 05-11-2016 03-31-2016 10-Q
40 03-23-2016 12-31-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 fda-acceptance-of-rocket-pharmaceuticals-lead-gene-therapy-application-reestablishes-momentum-for-stock

FDA accepts Rocket Pharmaceuticals' resubmission for Kresladi gene therapy in severe LAD-I, with a decision expected by Mar...

 chardan-capital-maintains-buy-on-rocket-pharmaceuticals-maintains-11-price-target

Chardan Capital analyst Geulah Livshits maintains Rocket Pharmaceuticals (NASDAQ:RCKT) with a Buy and maintains $11 price ta...

 the-fda-has-accepted-the-resubmission-of-rocket-pharmaceuticals-marketing-application-for-kresladi-marnetegragene-autotemcel-marne-cel-an-investigational-gene-therapy-for-severe-leukocyte-adhesion-deficiency-i-pdufa-date-is-march-28-2026

Prescription Drug User Fee Act (PDUFA) target action date is March 28, 2026All primary and secondary endpoints were met, and KR...

 leerink-partners-maintains-market-perform-on-rocket-pharmaceuticals-lowers-price-target-to-7

Leerink Partners analyst Mani Foroohar maintains Rocket Pharmaceuticals (NASDAQ:RCKT) with a Market Perform and lowers the p...

 fda-outlines-process-to-speed-up-rare-disease-therapy-approvals

FDA launches Rare Disease Evidence Principles to guide therapy reviews, offering new pathways for approval while raising questi...

 rocket-pharmaceuticals-cfo-aaron-ondrey-resigns-martin-wilson-appointed-interim-cfo-effective-september-8

Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers; Compensatory Arrangemen...

 the-european-medicines-agency-just-disclosed-that-rocket-pharmaceuticals-has-withdrawn-its-application-for-marketing-authorization-of-fanskya-the-ema-concluded-that-the-benefit-of-mozafancogene-autotemcel-did-not-outweigh-its-risks---ema

https://www.ema.europa.eu/en/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-fanskya-moz...

 b-of-a-securities-upgrades-rocket-pharmaceuticals-to-buy-raises-price-target-to-10

B of A Securities analyst Jason Zemansky upgrades Rocket Pharmaceuticals (NASDAQ:RCKT) from Neutral to Buy and raises the pr...

 chardan-capital-maintains-buy-on-rocket-pharmaceuticals-maintains-11-price-target

Chardan Capital analyst Geulah Livshits maintains Rocket Pharmaceuticals (NASDAQ:RCKT) with a Buy and maintains $11 price ta...

 fda-lifts-rocket-pharmaceuticals-study-hold-for-rare-disease-gene-therapy

Rocket Pharmaceuticals shares rise after FDA clears its pivotal RP-A501 trial for Danon disease with adjusted dosing and update...

 the-fda-lifts-clinical-hold-on-rocket-pharmaceuticals-pivotal-phase-2-trial-of-rp-a501-for-danon-disease

In its correspondence, the FDA confirmed that Rocket satisfactorily addressed issues outlined in the clinical hold. The FDA aut...

 chardan-capital-maintains-buy-on-rocket-pharmaceuticals-lowers-price-target-to-11

Chardan Capital analyst Geulah Livshits maintains Rocket Pharmaceuticals (NASDAQ:RCKT) with a Buy and lowers the price targe...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION